All In Biotech

Drug Trial Radar · NCT05196477

Study of the Outcomes of Olokizumab Therapy in Hospitalized Patients With SARS-CoV-2 (COVID-19) Infection

Multicentre Non-interventional Retrospective Cohort Study of the Outcomes of Olokizumab Therapy in Hospitalized Patients With SARS-CoV-2 (COVID-19) Infection

Last checked: Nov 20, 2026Latest source record: Jan 20, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

3,087

Actual

Start

Jul 14, 2021

Primary completion

Aug 29, 2022

Study completion Aug 29, 2022

Sponsor

Lead sponsor
R-PharmIndustry
Sponsor type
Industry
Collaborators
Almedis LLC; Data Management 365; ScienceFiles LLC
First posted
Jan 19, 2022

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study purpose was to assess the outcomes of therapy with olokizumab within complex therapy of Coronavirus disease 2019 (COVID-19) in hospitalised patients in real clinical practice setting. The study investigated patients' characteristics, disease progression, and efficacy and safety of olokizumab therapy.

Conditions

  • COVID-19

Interventions

  • OlokizumabDrug

    The details of taking olokizumab, including its route of administration, dose and frequency of taking the drug as part of routine clinical practice, will be registered in the electronic case report forms (eCRFs).

  • Standard therapyDrug

    Standard treatment (excluding administration of olokizumab, other interleukin (IL) (interleukin-1 and interleukin-17) inhibitors and Janus-kinase inhibitors.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The percentage of patients who died during hospital admission due to any reasonTime frame: up to 21 days

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • State Budgetary Healthcare Institution "Regional Hospital № 3"

    Chelyabinsk, Russia

  • State Budgetary Healthcare Institution "City Clinical Hospital named after F.I. Inozemtsev of Moscow Healthcare Department"

    Moscow, Russia

  • St. Petersburg State Budgetary Healthcare Institution "City Hospital No. 40 of the Kurortny District"

    Saint Petersburg, Russia

  • State Budgetary Institution of Healthcare of Tver region "Regional clinical hospital"

    Tver', Russia

  • Federal State Budgetary Educational Institution of Higher Education "Kazan State Medical University" under the Ministry of Health of the Russian Federation

    Kazan', Tatarstan Republic, Russia

  • Federal State Budgetary Educational Institution of Higher Education Bashkir State Medical University of the Ministry for Healthcare of the Russian Federation

    Ufa, The Republic of Bashkortostan, Russia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.